The company made its presence felt in the market by providing refractories solution and total customer satisfaction for over 30 years. The plant, located in Central Orissa at IPITATA Nagar ...

HarbisonWalker International is investing $13.9 million in Fulton, creating 11 new jobs with a modern facility expanding ...

Currently Corvus is enrolling patients in a registrational Phase 3 trial to evaluate soquelitinib to treat refractory ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

Eric Easom, the company's co-founder, chairman, president and chief executive officer, said recent data analysis indicate that epetraborole may provide clinical improvement in patients with ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Please find enclosed herewith extract of statement of Unaudited Consolidated Financial Results for the quarter and six months 30th September, 2024 published in newspapers, Business Standard -All ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...

Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral ... VIRX), a clinical-stage precision oncology company ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals (NASDAQ:SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline ...